CLAG-M | Search

临床试验

Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

计划入组 50 人 · 首次发布于 2012 年 1 月 20 日

招募中

NCT06660368

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

计划入组 52 人 · 首次发布于 2024 年 10 月 28 日

招募中

NCT04797767

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

计划入组 62 人 · 首次发布于 2021 年 3 月 15 日

药物

查看全部 866 →

Small Molecule

Approved

Cytarabine(Cytosar, Vyxeos, Vyxeos liposomal (previously Vyxeos))

生产企业：Pacira pharmaceuticals inc, App pharmaceuticals llc，另有 3 家

相关疾病：Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia，另有 7 项

C₉H₁₃N₃O₅ · Rx

M-5291

M-121101

机构

查看全部 137 →

BATEMAN, TIMOTHY M. M. MD

United States

COSTELLO, JOHN M.

United States

Florida A&M University

United States

资讯

查看全部 1365 →

去年

Actinium Pharmaceuticals Advances Antibody Radiation Conjugates for AML and Solid Tumors

3个月前

Actinium Pharmaceuticals Secures Canadian Patent Protection for Radiotherapy Programs in AML and Cell Therapy Conditioning

去年

临床试验

Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

药物

Cytarabine(Cytosar, Vyxeos, Vyxeos liposomal (previously Vyxeos))

M-5291

M-121101

机构

BATEMAN, TIMOTHY M. M. MD

COSTELLO, JOHN M.

Florida A&M University

资讯

Actinium Pharmaceuticals Advances Antibody Radiation Conjugates for AML and Solid Tumors

Actinium Pharmaceuticals Secures Canadian Patent Protection for Radiotherapy Programs in AML and Cell Therapy Conditioning

Actinium Pharmaceuticals Anticipates Key Data Readouts for AML Therapies